Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 11/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30175628 | 1.00 | PRKCZ (0.51) | PRKCZABL1ADORA2AADORA1PRKD2 | |
| SCHEMBL30175627 | 0.90 | ABL1 (0.44) | PRKCZABL1 | |
| SCHEMBL29897396 | 0.90 | PRKCZ (0.49) | PRKCZABL1PRKD2KMT2A | |
| SCHEMBL23301162 | 0.90 | PRKCZ (0.43) | PRKCZABL1RPS6KA2 | |
| SCHEMBL25043308 | 0.90 | ABL1 (0.44) | PRKCZABL1 | |
| SCHEMBL23332576 | 0.90 | ABL1 (0.44) | PRKCZABL1 | |
| SCHEMBL23301264 | 0.90 | PRKCZ (0.49) | PRKCZABL1PRKD2KMT2A | |
| SCHEMBL25043849 | 0.90 | PRKCZ (0.67) | PRKCZPRKD2 | |
| SCHEMBL25043297 | 0.90 | PRKCZ (0.67) | PRKCZPRKD2 | |
| SCHEMBL30175675 | 0.90 | PRKCZ (0.67) | PRKCZPRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| WO-2021084265-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021084264-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | PRKCZ 875/4885ABL1 444/4885ADORA2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.